Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
- Revenue in USD (TTM)5.90m
- Net income in USD-87.96m
- Incorporated2004
- Employees73.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zymeworks Inc | 62.20m | -113.67m | 946.15m | 294.00 | -- | 2.62 | -- | 15.21 | -1.51 | -1.51 | 0.8306 | 5.23 | 0.1192 | -- | 1.37 | 228,672.80 | -21.79 | -22.58 | -25.64 | -26.90 | -- | -- | -182.75 | -91.17 | -- | -- | 0.00009 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Upstream Bio Inc | -100.00bn | -100.00bn | 954.02m | 38.00 | -- | -- | -- | -- | -- | -- | -- | 4.30 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | 96.37 | -- | -60.28 | -- | -- | -- |
| Vir Biotechnology Inc | 78.62m | -533.34m | 957.15m | 587.00 | -- | 0.7658 | -- | 12.17 | -3.92 | -3.92 | 0.5794 | 9.08 | 0.0444 | -- | -- | 133,931.90 | -30.10 | -0.6081 | -32.71 | -0.7192 | 98.78 | -- | -678.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Cogent Biosciences Inc | 0.00 | -242.30m | 982.87m | 164.00 | -- | 4.86 | -- | -- | -2.48 | -2.48 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -65.53 | -49.53 | -74.36 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| 89bio Inc | 0.00 | -288.96m | 985.34m | 70.00 | -- | 2.35 | -- | -- | -2.91 | -2.91 | 0.00 | 3.56 | 0.00 | -- | -- | 0.00 | -62.93 | -45.50 | -67.67 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0859 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Applied Therapeutics Inc | -211.00k | -187.31m | 1.08bn | 37.00 | -- | 183.07 | -- | -- | -1.53 | -1.53 | -0.0017 | 0.0506 | -0.0028 | -- | -- | -8,440.00 | -246.85 | -140.37 | -- | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Gyre Therapeutics Inc | 191.34m | -76.96m | 1.10bn | 593.00 | -- | 15.95 | -- | 5.74 | -0.2281 | -0.2281 | 1.35 | 0.7366 | 2.83 | -- | 19.64 | 322,656.00 | -95.21 | -73.59 | -154.33 | -99.94 | 96.16 | -- | -33.64 | -205.62 | 3.29 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Mesoblast Ltd (ADR) | 5.90m | -87.96m | 1.10bn | 73.00 | -- | 2.42 | -- | 186.82 | -0.8761 | -0.8761 | 0.0598 | 4.21 | 0.0088 | -- | 3.21 | 80,849.31 | -13.14 | -12.62 | -14.38 | -13.97 | -166.30 | -109.14 | -1,490.28 | -692.63 | -- | -3.54 | 0.1984 | -- | -21.32 | -18.80 | -7.41 | -- | -0.5802 | -- |
| Pharvaris NV | 0.00 | -138.46m | 1.14bn | 82.00 | -- | 3.66 | -- | -- | -2.71 | -2.71 | 0.00 | 5.76 | 0.00 | -- | -- | 0.00 | -54.80 | -36.09 | -58.76 | -38.27 | -- | -- | -- | -- | -- | -41.69 | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -258.08m | 1.17bn | 268.00 | -- | 3.53 | -- | -- | -2.75 | -2.75 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -52.01 | -35.26 | -56.17 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0605 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Arcutis Biotherapeutics Inc | 138.71m | -195.54m | 1.20bn | 296.00 | -- | 7.65 | -- | 8.64 | -1.79 | -1.79 | 1.23 | 1.34 | 0.3799 | 1.04 | 3.49 | 468,608.10 | -53.55 | -65.64 | -75.79 | -71.72 | 89.57 | -- | -140.97 | -1,513.03 | 2.38 | -6.19 | 0.5664 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| CareDx Inc | 312.78m | -143.56m | 1.21bn | 635.00 | -- | 4.39 | -- | 3.87 | -2.70 | -2.70 | 5.95 | 5.15 | 0.6395 | 5.75 | 5.29 | 492,559.10 | -29.35 | -17.54 | -34.84 | -20.85 | 65.77 | 65.50 | -45.90 | -27.78 | 3.87 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
| Ardelyx Inc | 251.85m | -72.58m | 1.21bn | 267.00 | -- | 7.66 | -- | 4.82 | -0.3113 | -0.3113 | 1.08 | 0.6682 | 0.7664 | 3.76 | 5.22 | 943,254.70 | -22.09 | -46.14 | -26.72 | -57.32 | 85.16 | 88.15 | -28.82 | -240.87 | 3.87 | -5.94 | 0.3888 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Enliven Therapeutics Inc | 0.00 | -85.21m | 1.24bn | 57.00 | -- | 4.16 | -- | -- | -1.91 | -1.91 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -29.41 | -42.26 | -30.97 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Maravai Lifesciences Holdings Inc | 276.92m | -224.66m | 1.25bn | 580.00 | -- | 3.63 | -- | 4.52 | -1.65 | -1.65 | 2.04 | 1.37 | 0.1562 | 2.98 | 7.43 | 426,030.80 | -18.23 | 12.67 | -23.39 | 15.46 | 46.36 | 74.79 | -116.68 | 37.32 | 9.94 | -1.47 | 0.4746 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Aurinia Pharmaceuticals Inc | 220.36m | -22.55m | 1.26bn | 300.00 | -- | 3.23 | -- | 5.70 | -0.1582 | -0.1582 | 1.53 | 2.71 | 0.3991 | 0.7854 | 5.92 | 734,536.70 | -4.08 | -25.97 | -4.74 | -28.24 | 87.25 | -- | -10.23 | -137.64 | 5.11 | -- | 0.1725 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
Data as of Nov 22 2024. Currency figures normalised to Mesoblast Ltd's reporting currency: US Dollar USD
1.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Group One Trading LLCas of 30 Sep 2024 | 253.39k | 0.22% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 170.99k | 0.15% |
| Summit X LLCas of 30 Sep 2024 | 147.69k | 0.13% |
| Susquehanna Financial Group LLLPas of 30 Sep 2024 | 116.74k | 0.10% |
| Penbrook Management LLCas of 30 Sep 2024 | 107.28k | 0.09% |
| Prosperity Wealth Management, Inc.as of 30 Sep 2024 | 91.45k | 0.08% |
| Jane Street Capital LLCas of 30 Sep 2024 | 85.10k | 0.08% |
| Aperio Group LLCas of 30 Sep 2024 | 81.48k | 0.07% |
| Rockbridge Investment Management LLCas of 30 Sep 2024 | 49.15k | 0.04% |
| Lazari Capital Management, Inc.as of 30 Sep 2024 | 45.47k | 0.04% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
